These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37487345)

  • 1. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data.
    Amezcua L; Livingston T; Hayward B; Zhou J; Williams MJ
    Mult Scler Relat Disord; 2023 Sep; 77():104866. PubMed ID: 37487345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.
    Steinberg SC; Faris RJ; Chang CF; Chan A; Tankersley MA
    Clin Drug Investig; 2010; 30(2):89-100. PubMed ID: 20067327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
    Burks J; Marshall TS; Ye X
    Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis.
    Pardo G; Pineda ED; Ng CD; Sheinson D; Bonine NG
    J Health Econ Outcomes Res; 2022; 9(1):111-116. PubMed ID: 35586512
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
    Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
    J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
    Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
    Burkhard A; Toliver J; Rascati K
    J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
    [No Abstract]   [Full Text] [Related]  

  • 14. The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada.
    Gerber B; Cowling T; Chen G; Yeung M; Duquette P; Haddad P
    Mult Scler Relat Disord; 2017 Nov; 18():218-224. PubMed ID: 29141814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States.
    Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
    Clinicoecon Outcomes Res; 2023; 15():361-373. PubMed ID: 37234086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis.
    Hersh CM; Gorritz M; Chen CC; Tuly R; Gu Y; Gadkari A; Brown B; Shao Q
    Mult Scler Relat Disord; 2024 Nov; 91():105888. PubMed ID: 39388747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
    Higuera L; Carlin CS; Anderson S
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis.
    Hersh CM; Brook RA; Beren IA; Rohrbacker NJ; Lebson L; Henke C; Phillips AL
    J Med Econ; 2021; 24(1):479-486. PubMed ID: 33739915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.